Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing

Clin Cancer Res (2021) 27 (13): 3620–3629.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4746

Published: 01 July 2021

View article

Includes: Supplementary data

Journal Articles

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Ani S. Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio González-García, Nathan Standifer, Jennifer Cann, Nicholas Durham, Shahram Rahimian, Rakesh Kumar, Crystal S. Denlinger

Clin Cancer Res (2020) 26 (23): 6196–6203.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-0452

Published: 01 December 2020

View article

Includes: Supplementary data

Journal Articles

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clin Cancer Res (2020) 26 (21): 5579–5587.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-1215

Published: 02 November 2020

View article

Includes: Supplementary data

Journal Articles

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Melissa L. Johnson, Albert C. Lockhart, Kathleen Moore, Gerald S. Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Lee S. Rosen, Glen J. Weiss, Rom S. Leidner, Jingjin Li, Anne Paccaly, Minjie Feng, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury, Marka R. Crittenden

Clin Cancer Res (2020) 26 (5): 1025–1033.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-2609

Published: 02 March 2020

View article

Includes: Supplementary data

Journal Articles

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Karen A. Autio, Valentina Boni, Rachel W. Humphrey, Aung Naing

Clin Cancer Res (2020) 26 (5): 984–989.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-1457

Published: 02 March 2020

View article

Journal Articles

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers

Vivek Subbiah, Ravi Murthy, David S. Hong, Robert M. Prins, Chitra Hosing, Kyle Hendricks, Deepthi Kolli, Lori Noffsinger, Robert Brown, Mary McGuire, Siquing Fu, Sarina Piha-Paul, Aung Naing, Anthony P. Conley, Robert S. Benjamin, Indreshpal Kaur, Marnix L. Bosch

Clin Cancer Res (2018) 24 (16): 3845–3856.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2707

Published: 14 August 2018

View article

Includes: Supplementary data

Journal Articles

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Clin Cancer Res (2018) 24 (1): 181–188.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2007

Published: 02 January 2018

View article

Includes: Supplementary data

Journal Articles

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act

Kenneth L. Kehl, Cheryl P. Fullmer, Siqing Fu, Goldy C. George, Kenneth R. Hess, Filip Janku, Daniel D. Karp, Shumei Kato, Cynthia K. Kizer, Razelle Kurzrock, Aung Naing, Shubham Pant, Sarina A. Piha-Paul, Vivek Subbiah, Apostolia M. Tsimberidou, David S. Hong

Clin Cancer Res (2017) 23 (15): 4155–4162.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-3027

Published: 01 August 2017

View article

Includes: Supplementary data

Journal Articles

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Clin Cancer Res (2017) 23 (6): 1388–1396.

DOI: https://doi.org/10.1158/1078-0432.CCR-16-1432

Published: 14 March 2017

View article

Includes: Supplementary data

Journal Articles

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqing Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Goldy C. George, Lucy Xu, Robert Shumaker, Min Ren, Jennifer Mink, Cynthia Bedell, Corina Andresen, Pallavi Sachdev, James P. O'Brien, John Nemunaitis

Clin Cancer Res (2015) 21 (21): 4801–4810.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-3063

Published: 01 November 2015

View article

Includes: Supplementary data

Journal Articles

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

Denis L.F. Jardim, Chad Tang, Debora De Melo Gagliato, Gerald S. Falchook, Kenneth Hess, Filip Janku, Siqing Fu, Jennifer J. Wheler, Ralph G. Zinner, Aung Naing, Apostolia M. Tsimberidou, Vijaykumar Holla, Marylin M. Li, Sinchita Roy-Chowdhuri, Raja Luthra, Ravi Salgia, Razelle Kurzrock, Funda Meric-Bernstam, David S. Hong

Clin Cancer Res (2014) 20 (24): 6336–6345.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1293

Published: 14 December 2014

View article

Includes: Supplementary data

Journal Articles

Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic

Chad Tang, Kenneth Hess, Denis Leonardo F. Jardim, Debora De Melo Gagliato, Apostolia M. Tsimberidou, Gerald Falchook, Siqing Fu, Filip Janku, Aung Naing, Sarina Piha-Paul, Vivek Subbiah, Jennifer Wheler, Ralph G. Zinner, Razelle Kurzrock, Lee M. Ellis, Funda Meric-Berstam, David S. Hong

Clin Cancer Res (2014) 20 (23): 5956–5963.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-1582

Published: 30 November 2014

View article

Includes: Supplementary data

Journal Articles

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

Apostolia-Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape, Yang Ye, Razelle Kurzrock, Donald Berry

Clin Cancer Res (2014) 20 (18): 4827–4836.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-0603

Published: 14 September 2014

View article

Includes: Supplementary data

Journal Articles

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Ana M. Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, Gerald Falchook, David Hong, Argun Akcakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, Razelle Kurzrock

Clin Cancer Res (2013) 19 (19): 5474–5484.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-3110

Published: 01 October 2013

View article

Includes: Supplementary data

Journal Articles

Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors

David Hong, Rabih Said, Gerald Falchook, Aung Naing, Stacy Moulder, Apostolia-Maria Tsimberidou, Gerald Galluppi, Naveen Dakappagari, Chris Storgard, Razelle Kurzrock, Lee S. Rosen

Clin Cancer Res (2013) 19 (17): 4824–4831.

DOI: https://doi.org/10.1158/1078-0432.CCR-13-0477

Published: 02 September 2013

View article

Includes: Supplementary data

Journal Articles

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Apostolia-Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra, Yang Ye, Sijin Wen, Donald Berry, Razelle Kurzrock

Clin Cancer Res (2012) 18 (22): 6373–6383.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1627

Published: 14 November 2012

View article

Includes: Supplementary data

Journal Articles

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

John Moroney, Siqing Fu, Stacy Moulder, Gerald Falchook, Thorunn Helgason, Charles Levenback, David Hong, Aung Naing, Jennifer Wheler, Razelle Kurzrock

Clin Cancer Res (2012) 18 (20): 5796–5805.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-1158

Published: 14 October 2012

View article

Journal Articles

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer Wheler, Donald Lawrence, Joseph Paul Eder, Colin J. Meyer, Deborah A. Ferguson, James Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Kufe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube

Clin Cancer Res (2012) 18 (12): 3396–3406.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2703

Published: 14 June 2012

View article

Includes: Supplementary data

Journal Articles

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

Jennifer Wheler, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock

Clin Cancer Res (2012) 18 (10): 2922–2929.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2217

Published: 14 May 2012

View article

Includes: Supplementary data

Journal Articles

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph Ludwig, Helen X. Chen, Laurence A. Doyle, Razelle Kurzrock

Clin Cancer Res (2012) 18 (9): 2625–2631.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0061

Published: 30 April 2012

View article

NARROW

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic

Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic

Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only